Regulations.gov document
Attachment 2 Controlled Correspondence (Nicardipine Hydrochloride NDA019734) Letter from…
Supporting & Related Material · FDA-2019-P-1525 · posted Apr 30, 2019
Key facts
| Document ID | FDA-2019-P-1525-0004 |
|---|---|
| Title | Attachment 2 Controlled Correspondence (Nicardipine Hydrochloride NDA019734) Letter from FDA OGD CDER to Baxter Healthcare Corporation re Citizen Petition from Baxter Healthcare Corporation |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2019-P-1525 |
| Posted | Apr 30, 2019 |
| Effective date | Oct 26, 2018 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: